Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15994257 | 0.85 | AR (0.47) | ARSLC22A12KCNH2EPAS1 | |
| SCHEMBL11100867 | 0.80 | AR (0.53) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL12216024 | 0.80 | AR (0.50) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL5949965 | 0.78 | AR (0.56) | ARSLC22A12EPAS1 | |
| SCHEMBL378894 | 0.78 | SLC22A12 (0.46) | ARSLC22A12EPAS1 | |
| SCHEMBL378963 | 0.77 | AR (0.50) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL14437173 | 0.76 | AR (0.52) | ARSLC22A12EPAS1 | |
| SCHEMBL2446602 | 0.75 | MAPT (0.50) | ARSLC22A12 | |
| SCHEMBL9889477 | 0.74 | SLC22A12 (0.51) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL19057971 | 0.74 | AR (0.47) | ARSLC22A12KCNH2EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160002210-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002210-A1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CYP3A7, CYP3A5, CYP3A43 | AR 3031/4885SLC22A12 3300/4885HTR2A 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.